Mutations in tricarboxylic acid (TCA) cycle enzymes such as isocitrate dehydrogenase 2 (IDH2), succinate dehydrogenase, and fumarate hydratase are frequently found in human cancers [101,102], and the inhibitor of mutant IDH2, enasidenib, was approved by the FDA to treat acute myeloid leukemia [103,104]. The gene discussed is IDH2; the disease is acute myeloid leukemia.